MedTrace Logo

A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

NCT01280656 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 660

Last updated 2016-11-29

Study results available
· View outcomes & findings →

Summary

This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Conventional Interferon

Conventional interferon according to the standard of care and aligned with the local prescription instructions

DRUG

Peginterferon Alfa-2a

Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions

DRUG

Peginterferon Alfa-2b

Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions

DRUG

Ribavirin

Ribavirin according to the standard of care and aligned with the local prescription instructions

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-11-30
Completion
2013-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01280656 on ClinicalTrials.gov